Zanamivir Hydrate

CHEMBL5315117 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
350.3 g/mol
LogP
Phase
4

Zanamivir hydrate is a hydrated form of zanamivir, an inhaled neuraminidase inhibitor that blocks influenza virus neuraminidase to prevent viral release and spread within the respiratory tract. The hydrate form represents a physicochemical state of the molecule used in pharmaceutical characterization and manufacturing. Clinically, it is equivalent in activity to anhydrous zanamivir for treatment and prevention of influenza infections.

Peso Molecular

350,3300 g/mol

TPSA

202,00 Ų

Mecanismo de Ação

Inhibits viral neuraminidase, preventing the release of newly formed virus particles from infected cells and limiting viral spread within the respiratory tract.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits viral neuraminidase, preventing the release of newly formed virus particles from infected cells and limiting viral spread within the respiratory tract.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1NC(=N)N.O

InChI

InChI=1S/C12H20N4O7.H2O/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17;/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16);1H2/t5-,6+,8+,9+,10+;/m0./s1

Molecular Formula

C12H22N4O8

HBD / HBA

8 / 9

Ligações Rotacionáveis

6

Átomos Pesados

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

Zanamivir hydrate is a hydrated form of zanamivir, an inhaled neuraminidase inhibitor that blocks influenza virus neuraminidase to prevent viral release and spread within the respiratory tract. The hydrate form represents a physicochemical state of the molecule used in pharmaceutical characterization and manufacturing. Clinically, it is equivalent in activity to anhydrous zanamivir for treatment and prevention of influenza infections.

Inhibits viral neuraminidase, preventing the release of newly formed virus particles from infected cells and limiting viral spread within the respiratory tract.

Yes, Zanamivir Hydrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5315117. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 636424. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.